HAYWARD, Calif., March 17, 2015 /PRNewswire/ -- Anthera
Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced
that it intends to offer and sell shares of its common stock in an
underwritten public offering. The Company expects to grant the
underwriters a 30-day option to purchase up to an additional 15% of
the shares of common stock offered in the public offering to cover
over-allotments, if any. The Company intends to use the net
proceeds from the offering for clinical research
and development and general corporate purposes. The
offering is subject to market and other conditions, and there can
be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the
offering.
Piper Jaffray & Co. is acting
as sole underwriter in the offering.
The securities described above are being offered by the Company
pursuant to a shelf registration statement previously filed with,
and declared effective by, the Securities and Exchange Commission
(the "SEC"). A preliminary prospectus supplement and
accompanying prospectus relating to the offering will be filed with
the SEC and will be available on the SEC's website at
http://www.sec.gov. Copies of the preliminary prospectus
supplement and the accompanying prospectus relating to this
offering, when available, may be obtained from Piper Jaffray & Co., Attention: Prospectus
Department, at 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at
800-747-3924 or by email at prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or other jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or jurisdiction.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused
on advancing the development and commercialization of innovative
medicines that benefit patients with unmet medical needs.
Safe Harbor Statement
Any statements contained in this press release that refer to
future events or other non-historical matters, including statements
that are preceded by, followed by, or that include such words as
"estimate," "intend," "anticipate," "believe," "plan," "goal,"
"expect," "project," or similar statements, are forward-looking
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include statements about Anthera's
expectations with respect to its proposed offering, including its
intention to offer and sell shares, its intention to grant the
underwriters an over-allotment option and its intended use of
proceed from the offering. Such statements are based on
Anthera's expectations as of the date of this press release and are
subject to certain risks and uncertainties that could cause actual
results to differ materially, including but not limited to the
risks and uncertainties associated with market conditions and the
satisfaction of customary closing conditions related to the
proposed offering, as well as those set forth in Anthera's public
filings with the SEC, including Anthera's Annual Report on Form
10-K for the year ended December 31,
2014. Anthera disclaims any intent or obligation to update
any forward-looking statements, whether because of new information,
future events or otherwise, except as required by applicable
law.
CONTACT: Dennis Lutz of Anthera
Pharmaceuticals, Inc., dlutz@anthera.com or 510.856.5598.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/anthera-pharmaceuticals-announces-proposed-public-offering-of-common-stock-300051950.html
SOURCE Anthera Pharmaceuticals, Inc.